Research Article
BibTex RIS Cite

Adjuvant Treatment in Soft Tissue Sarcoma (Single Center Experience)

Year 2022, Volume: 6 Issue: 3, 283 - 289, 27.12.2022
https://doi.org/10.29058/mjwbs.1061890

Abstract

Aim: Soft tissue sarcomas are a type of cancer with more than 50 histological subgroups, constituting
approximately 1% of malignancies. It is seen at a rate of about 5/100000. Even in patients with local
disease, the survival rate is 59%; pushed clinicians to different searches. Although many studies and
meta-analyses show that patients receiving adjuvant chemotherapy have a prolonged disease-free
survival, there is a difference between studies on overall survival. In our study, we examined patients
who received adjuvant chemotherapy in our center for soft tissue sarcoma.
Material and Methods: The study was planned retrospectively. In Istanbul University Oncology
Institute Medical Oncology Polyclinic; In this study, patients with soft tissue sarcoma over the age of
18 who were operated locally or locally advanced, or metastatic, who underwent both local surgery
and metastasectomy and subsequently received adjuvant treatment, were recruited and the effect of
adjuvant chemotherapy on the course of the disease was investigated.
Results: Forty patients were included in the study. The patients were followed up for a median of 53 months (5-155). 55% of the patients are Stage 1 (10% Stage 1A, 45% Stage 1B), 15% are Stage 3 (5% Stage 3A, 10% are Stage 3B), 30% are Stage 4. Patients received a median of four cycles of adjuvant chemotherapy, and 80% of patients received Adriamycin - Ifosfamide. While the disease relapses in half of the patients, the median disease-free survival in patients with relapse is 12 months. The median overall survival of patients was 39 months.
Conclusion: As a result of our study, we think that adjuvant therapy may contribute to both disease-free and total survival, and that this contribution may be in both extremity and extra-extremity soft tissue sarcomas, but we think that prospective studies with larger patient numbers would be more useful to reach a definite conclusion.

References

  • Referans1: 1: Poon E, Quek R. Soft tissue sarcoma in Asia. Chin Clin Oncol. 2018 Aug;7(4):46. doi: 10.21037/cco.2018.08.06. PMID: 30173536.
  • Referans2: Galy-Bernadoy C, Garrel R. Head and neck soft-tissue sarcoma in adults. Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Feb;133(1):37-42. doi: 10.1016/j.anorl.2015.09.003. Epub 2015 Sep 26. PMID: 26403655.
  • Referans3: Abaricia S, Van Tine BA. Management of localized extremity and retroperitoneal soft tissue sarcoma. Curr Probl Cancer. 2019 Aug;43(4):273-282. doi: 10.1016/j.currproblcancer.2019.06.002. Epub 2019 Jun 15. PMID: 31221500.

Yumuşak Doku Sarkomlarında Adjuvan Tedavi (Tek Merkez Deneyimi)

Year 2022, Volume: 6 Issue: 3, 283 - 289, 27.12.2022
https://doi.org/10.29058/mjwbs.1061890

Abstract

Amaç: Yumuşak doku sarkomları, malignitelerin yaklaşık %1’ini oluşturan, 50’den fazla histolojik alt
grubu olan bir kanser türüdür. Adjuvan kemoterapi alan hastaların hastalıksız sağkalımlarının uzadığını
birçok çalışma ve metaanaliz gösterse de, genel sağkalıma ilişkin çalışmalar arasında fark vardır.
Çalışmamızın amacı, merkezimizde yumuşak doku sarkomu nedeniyle adjuvan kemoterapi uygulanan
hastaların klinik seyirlerini incelemektir.
Gereç ve Yöntemler: Çalışma retrospektif olarak planlanmıştır. İstanbul Üniversitesi Onkoloji Enstitüsü
Tıbbi Onkoloji polikliniğinde; lokal, lokal ileri olup opere olan veya metastatik olup hem lokal cerrahi
hem de metastazektomi yapılan ve sonrasında adjuvan tedavi almış 18 yaşın üstündeki yumuşak doku
sarkomu hastaları alınmış ve adjuvan kemoterapinin hastalığın seyrine olan etkisi incelenmiştir.
Bulgular: 40 hasta çalışmaya dahil edildi. Hastalar medyan 53 ay (5-155) takip edildi. Hastaların
%55’i Evre 1 (%10 Evre 1A, %45 Evre 1B), %15 Evre 3 (%5 Evre 3A, %10 Evre 3B), %30 Evre 4’tür.
Hastalara medyan dört kür adjuvan kemoterapi verildi ve hastaların %80’i Adriamisin - İfosfamid aldı.
Hastaların yarısında hastalık nüks ederken, nüks eden hastalarda hastalıksız sağkalım medyan 12
aydır. Hastaların medyan toplam sağkalımı 39 aydır.
Sonuç: Yaptığımız çalışmanın sonucunda adjuvan tedavinin hem hastalıksız hem de total sağkalımı
katkısı sağlayabileceğini ve bu katkının hem ekstremite hem de ekstremite dışı yumuşak doku
sarkomlarında olabileceğini düşünüyoruz ama kesin bir kanıya varmak için daha geniş hasta sayıları ile
yapılacak prospektif çalışmaların daha yararlı olabileceğini düşünüyoruz.

References

  • Referans1: 1: Poon E, Quek R. Soft tissue sarcoma in Asia. Chin Clin Oncol. 2018 Aug;7(4):46. doi: 10.21037/cco.2018.08.06. PMID: 30173536.
  • Referans2: Galy-Bernadoy C, Garrel R. Head and neck soft-tissue sarcoma in adults. Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Feb;133(1):37-42. doi: 10.1016/j.anorl.2015.09.003. Epub 2015 Sep 26. PMID: 26403655.
  • Referans3: Abaricia S, Van Tine BA. Management of localized extremity and retroperitoneal soft tissue sarcoma. Curr Probl Cancer. 2019 Aug;43(4):273-282. doi: 10.1016/j.currproblcancer.2019.06.002. Epub 2019 Jun 15. PMID: 31221500.
There are 3 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Research Article
Authors

Metin Pehlivan 0000-0002-7214-9563

Ayça İribaş 0000-0002-1686-7114

Bilge Bilgiç This is me 0000-0001-9231-1743

Mert Başaran This is me 0000-0001-5437-134X

Meltem Ekenel This is me 0000-0003-1887-5561

Publication Date December 27, 2022
Acceptance Date August 8, 2022
Published in Issue Year 2022 Volume: 6 Issue: 3

Cite

Vancouver Pehlivan M, İribaş A, Bilgiç B, Başaran M, Ekenel M. Yumuşak Doku Sarkomlarında Adjuvan Tedavi (Tek Merkez Deneyimi). Med J West Black Sea. 2022;6(3):283-9.

Medical Journal of Western Black Sea is a scientific publication of Zonguldak Bulent Ecevit University Faculty of Medicine.

This is a refereed journal, which aims at achieving free knowledge to the national and international organizations and individuals related to medical sciences in publishedand electronic forms.

This journal is published three annually in April, August and December.
The publication language of the journal is Turkish and English.